Venus Concept Inc. is undergoing a bit of nip and tuck in efforts to improve the company’s cash flow position and obtain long-term stability. As part of the reconfiguration, the company plans to shed 18% of its workforce with layoffs starting on Feb. 6. In Israel and North America. The executive leadership team also experienced some plumping and extraction.

Varian’s Halcyon and Ethos radiotherapy systems received two regulatory nods in short succession, with both U.S. FDA 510(k) clearance and CE marking. In addition, the company reported that the first patient in the world underwent treatment with a Halcyon system with Hypersight last week.

Dxcover Ltd. raised $9.25 million (£7.5 million) in a series A fundraising round and received a grant of $2.7 million (£2.2 million) from the European Innovation Council to support development of the company’s liquid biopsy platform for the detection of multiple early-stage cancers. Existing investors Eos Advisory LLP, Mercia Asset Management plc, Scottish Enterprise, University of Strathclyde, SIS Ventures and Norcliffe Capital led the round, which was also joined by Mark Banforth of Thairm Bio.

Aktiia SA’s wrist-worn, continuous blood pressure monitor, which has been in use in the EU since 2021, could soon be coming to the U.S. The Aktiia bracelet uses photoplethysmography, the technology perhaps best known for providing blood oxygenation readings via pulse oximeters, and an algorithm based on thousands of readings to estimate blood pressure as wearers go about their daily activities.

Royal Philips NV revealed plans to cut a further 6,000 jobs on top of the 4,000 announced in October as it sought to stabilize the business and improve its operational performance going into 2023. In total, the company will reduce its workforce by about 13%. Philip’s fourth quarter results came in ahead of consensus expectations, but the company still posted a loss of €105 million (US$108.2 million).

A meta-analysis found no difference in outcomes between autograft nerve repair and repair using Axogen Inc.’s Avance nerve grafts across all types of nerves and gap lengths up to 70 millimeters. Axogen’s allograft nerves allow patients to avoid the potential complications associated with harvesting the individual’s own nerve to use in repair. The study was published in Plastic and Reconstructive Surgery in January.

GSR Ventures, a venture firm focused on early stage digital health companies, forecasts a much brighter investment picture for 2023 following a hard reset in 2022, said GSR Partner Sunny Kumar in an interview with BioWorld at the J.P. Morgan Healthcare Conference in San Francisco.

The U.S. FDA approved the Proclaim XR spinal cord stimulation system by Abbott Laboratories for painful diabetic peripheral neuropathy (DPN). The system offers an alternative to patients for whom oral medications do not provide sufficient relief. About half of individuals with diabetes will eventually develop peripheral neuropathy which primarily damages the nerves running down the legs to the feet.

Biobeat Technologies Ltd. expanded its U.S. FDA-cleared remote patient monitoring offerings with a double nod from the agency for its sensors to monitor stroke volume and cardiac output. The two new indications join its capabilities for measuring the five vital signs assessed in any medical visit—blood pressure, blood oxygen saturation, pulse rate, respiratory rate and body temperature—all of which can be done using photoplethysmography (PPG) on sensors embedded on either a short-term chest patch or a more durable wrist monitor.